GLP-1 Treatment Options

How to compare injections and tablets, understand what each medication is approved for, and discuss the options with your clinician.

Choosing a GLP-1 medication starts with a question that brand comparisons often skip. What are you trying to treat? Someone looking for better blood sugar control may consider a different product from someone seeking long-term weight management. A person with type 2 diabetes and chronic kidney disease may have different priorities again.

The formulation matters, too. Some GLP-1 medications are weekly injections. Others are daily tablets, and some tablets have specific instructions about food, water, and other medications. Even products that share an active ingredient can have different doses and approved uses. This guide uses U.S. FDA approvals and focuses on how to compare the options in a real treatment decision. www.niddk.nih.gov

Which medications count as GLP-1 treatment options?

GLP-1 receptor agonists activate the receptor for glucagon-like peptide-1, a hormone your body releases after eating. Depending on the medication, activating this pathway can help the pancreas release insulin when glucose is elevated, slow stomach emptying, and influence appetite. Semaglutide, liraglutide, dulaglutide, and orforglipron are examples of GLP-1 receptor agonists. Tirzepatide is often included in the same conversation because it activates the GLP-1 receptor as well as a second receptor called GIP. journals.physiology.org

When someone recommends a drug by brand name, check three things: its active ingredient, its formulation, and the condition it’s approved to treat. The table shows examples you may encounter. It’s a starting point for a conversation, since some products have additional indications and eligibility varies by formulation. www.niddk.nih.gov

The rows group products by ingredient. They do not indicate that the products can be swapped at the same dose. The FDA labeling for Rybelsus and Ozempic tablets, for example, specifically says they aren’t interchangeable milligram for milligram. If a pharmacy or insurer suggests a switch, ask your prescriber what the new prescription and transition plan should be. www.niddk.nih.gov

Compare options by the condition you want to treat

Type 2 diabetes

If your main goal is to lower blood sugar, ask how a medication fits with your current treatment and what change you and your clinician hope to see in your A1C or glucose readings. The choice may also depend on other health conditions. For example, U.S. labeling for Rybelsus and Ozempic tablets includes a cardiovascular risk-reduction indication for adults with type 2 diabetes who are at high risk for major cardiovascular events. If heart or kidney disease is part of the decision, ask which benefit has been shown for the exact product and for people with your health history. accessdata.fda.gov

Bring a list of your current medicines, including doses and when you take them. If you use insulin or a sulfonylurea, adding certain GLP-1 drugs can increase the risk of low blood sugar. Ask whether your care team wants you to check glucose more often when you start, what readings should prompt a call, and whether any existing treatment needs to be adjusted. Follow the plan they give you for dose changes. accessdata.fda.gov

Long-term weight management

Common U.S. eligibility criteria for adult weight-management treatment include a BMI of 30 or higher, or a BMI of 27 or higher with a weight-related health condition, such as high blood pressure or type 2 diabetes. Meeting a threshold starts the conversation. Your clinician also considers your health history, other medications, expected benefit, potential side effects, and whether you can maintain access to treatment. www.niddk.nih.gov

Decide what you’d want to review at follow-up. Weight is one measure. You might also discuss whether you can eat and drink comfortably, how your appetite has changed, and whether the treatment is helping with the health concern that led you to consider it. A medication may be effective in a trial and still be difficult for an individual to continue because of side effects, cost, or the daily routine it requires. www.niddk.nih.gov

Obstructive sleep apnea or established cardiovascular disease

Some products have approvals beyond diabetes or weight management. Zepbound is FDA-approved to treat moderate to severe obstructive sleep apnea in adults with obesity. Wegovy has an indication to reduce the risk of major cardiovascular events in adults with established cardiovascular disease and either overweight or obesity. These approvals apply to specific groups. If you use a treatment such as positive airway pressure for sleep apnea, discuss how a new medication fits into your plan before making any changes. FDA

Weekly injection, daily injection, or tablet?

Weekly injections

Weekly injectable options include semaglutide and tirzepatide products. A weekly schedule may suit someone who prefers to set aside one day for medication. It also means learning how to use the prescribed device, where to inject, how to store it, and what to do if a dose is late. Ask your pharmacist to show you the specific device you’ll use. Pens and vials can have different instructions, even within the same brand. www.accessdata.fda.gov

Think about an ordinary month. If you travel often, ask how to handle storage and what to do if your planned injection day falls on a travel day. If you work rotating shifts, pick a reminder you’ll see even when your usual routine changes. Ask for the missed-dose instructions in writing so you don’t have to reconstruct them when you need them. www.accessdata.fda.gov

Daily injections

Liraglutide is an example of a daily injection. If a daily schedule suits you, ask how to attach it to a routine you already follow. If you’re switching from a weekly medication, get explicit instructions on when to start the new drug. The timing and dose of one product don’t automatically carry over to the other. www.niddk.nih.gov

Daily tablets

The daily routine depends on the tablet. Oral semaglutide products have instructions about taking the tablet on an empty stomach with a limited amount of plain water and waiting at least 30 minutes before eating, drinking other beverages, or taking other oral medicines. Foundayo, an oral GLP-1 option for weight management, can be taken with or without food. If you take several morning medicines, ask a pharmacist to help you work out the order and timing. accessdata.fda.gov

For example, if you take another medication first thing in the morning and leave for work soon afterward, a tablet with fasting instructions may require more planning than you expect. If you travel frequently and are concerned about carrying injection supplies, a tablet may appeal to you. Walk through how you’d take each option on a busy day as well as on a quiet one.

How should you compare weight-loss results?

A head-to-head trial can tell you more about two treatments than percentages pulled from unrelated studies. In SURMOUNT-5, adults with obesity who did not have type 2 diabetes were assigned to weekly injections of tirzepatide or semaglutide. At 72 weeks, the estimated average weight reduction was 20.2% with tirzepatide and 13.7% with semaglutide. The trial compared maximum tolerated doses of 10 or 15 mg of tirzepatide with 1.7 or 2.4 mg of semaglutide. It was funded by the maker of tirzepatide. PubMed

Those figures describe the participants and doses studied. The trial did not compare tirzepatide with oral semaglutide or with the 7.2 mg Wegovy injection the FDA subsequently approved for certain adults. It also excluded people with type 2 diabetes. If a headline quotes a percentage, check who was in the study, which formulation and dose they took, how long they were followed, and whether the comparison was direct. PubMed

At an appointment, ask what result would justify continuing the treatment in your case. A trial average can help set expectations. Your follow-up should also account for which dose you can tolerate and whether the medication is helping with the condition you started it to treat. www.niddk.nih.gov

What to know about dose increases and side effects

Many GLP-1 medications start at a lower dose and increase in steps. The schedule is specific to the product. A starting dose is often part of getting used to treatment, so ask when it’s reasonable to assess results. If symptoms are still interfering with eating or drinking when a dose increase is due, contact your prescriber for instructions. www.accessdata.fda.gov

Common side effects include nausea, diarrhea, vomiting, constipation, and abdominal discomfort. Let your prescriber know if symptoms persist or make it hard to eat or drink. Ongoing vomiting or diarrhea can lead to dehydration. Get urgent medical advice for severe abdominal pain that doesn’t go away, especially if it spreads to your back, or for repeated vomiting that prevents you from keeping fluids down. Seek emergency care for trouble breathing or swelling of your face, lips, tongue, or throat. www.accessdata.fda.gov

Before starting, bring up the following if they apply to you:

• A personal or family history of medullary thyroid carcinoma, or a diagnosis of MEN2. The labels for Wegovy and Zepbound list these as reasons to avoid those drugs. Their boxed warnings describe thyroid tumors observed in rodents. Whether the drugs cause these tumors in humans is unknown. www.accessdata.fda.gov
• Severe digestive problems or a history of pancreatitis. Tell your prescriber about conditions such as severe gastroparesis, which slows stomach emptying, and ask how your history affects the choice. www.accessdata.fda.gov
• An upcoming procedure with anesthesia or deep sedation. Tell the procedure team which medication you take and when you last took it. Follow their instructions for the procedure. accessdata.fda.gov
• Pregnancy plans or use of oral birth control. Ask about the specific product. The Wegovy label advises stopping at least two months before a planned pregnancy when used for weight reduction. The Zepbound label advises people who use oral hormonal contraception to switch to a nonoral method or add a barrier method for four weeks after starting and for four weeks after each dose increase. www.accessdata.fda.gov

Compare cost and access before your first prescription

Ask your insurer or pharmacy about the exact brand, formulation, and indication on the prescription. If you’re quoted a price, check what it applies to. Is it for the first fill or for continuing treatment? Does the price change when the dose increases? If there’s a prior authorization, ask who will submit it and what information the insurer needs. Knowing how you’ll refill the medication is part of deciding whether the plan fits your life. www.niddk.nih.gov

If you’re considering an online service, ask who prescribes the medication, which pharmacy dispenses it, and who answers questions if you have side effects or need a refill. Find out whether you’ll receive an FDA-approved or a compounded product. Compounded drugs don’t undergo FDA review for safety, effectiveness, and quality before marketing. The FDA has received reports of dosing errors with compounded injectable products and advises patients to fill prescriptions at a state-licensed pharmacy. www.fda.gov

If an approved product is unaffordable or unavailable, tell your prescriber before you run out. They can discuss other treatment options and explain whether you need to change how you monitor blood sugar or how you restart after a gap. Keep the old packaging or a photo of its label so the pharmacist can see exactly what you were taking. www.fda.gov

Plan for the possibility of stopping or switching

Talk with your prescriber before stopping or switching, particularly if the medication helps manage your blood sugar. Ask whether you’ll need closer monitoring, a different medication, or a follow-up visit sooner than usual. If you’re switching formulations or brands, get clear instructions on when to take your last dose of the old product and your first dose of the new one. www.cdc.gov

Appetite and weight can change when treatment ends. In the STEP 1 extension, participants who had used semaglutide regained about two-thirds of the weight they’d lost, on average, in the year after both the medication and the trial’s structured lifestyle intervention ended. That was the average for a particular study group. It gives you a reason to discuss maintenance early, including what you’ll do if hunger returns or weight begins trending upward. pubmed.ncbi.nlm.nih.gov

Questions to take to your appointment

1. What condition are we treating, and which products are approved for it? Ask about the exact formulation and why it fits your medical history.
2. How would I take it on a typical day or week? Walk through meal timing, other medicines, storage, and missed doses.
3. What would count as a good response? Ask what you’ll track and when you’ll review whether it’s helping.
4. What should I do if side effects interfere with meals or fluids? Get instructions before the first dose increase.
5. What will it cost to stay on treatment? Check coverage and refill costs beyond the starting prescription.
6. What happens if I need to stop, restart, or switch? Ask who to contact and what to monitor in the meantime. www.niddk.nih.gov

If you’re comparing two options, write the answers down side by side. You may find that one fits your treatment goal, while the other raises a question about side effects, timing, or cost that you want to resolve before filling the prescription.